On the discovery and development of CFTR chloride channel activators.

abstract：:The impact of depression on physical disability is undisputed. There is convincing evidence that depression increases the subsequent risk for physical disability and, in turn, physical disability results in increased depressive symptoms. Moreover, depression affects also the earlier stages of the disablement process (...

journal_title：Current pharmaceutical design

authors： Milaneschi Y,Penninx BW

更新日期：2014-01-01 00:00:00

abstract：:Arterial thromboembolism is a sudden obstruction of arterial blood flow caused by dislodgment of a blood clot from the site of its formation. Atrial fibrillation (AF) is the most common cardiac arrhythmia and a major risk factor for arterial thromboembolism in clinical practice. Most of AF-related arterial thromboembo...

journal_title：Current pharmaceutical design

authors： Potpara TS,Lip GY

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Approximately 10-15% of patients on DOACs have to interrupt their anticoagulant before an invasive procedure every year. The perioperative management and monitoring of DOACs have proved to be challenging, as differences in patients' status and in the invasiveness of each procedure develop different situation...

journal_title：Current pharmaceutical design

authors： Kouvelos G,Matsagkas M,Rousas N,Nana P,Mpatzalexis K,Stamoulis K,Giannoukas A,Arnaoutoglou E

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Polycystic ovary syndrome (PCOS) is a frequent female reproductive endocrine disease. It has been associated with a number of severe reproductive and metabolic abnormalities. However, there are still open questions especially regarding the best long-term management. METHODS:We summarized the literature focu...

journal_title：Current pharmaceutical design

authors： Ruan X,Li M,Mueck AO

更新日期：2018-01-01 00:00:00

abstract：:Hypertension is the most common medical disorder during pregnancy. Approximately 70 percent of women diagnosed with hypertension during pregnancy will have gestational hypertension-preeclampsia. The term gestational hypertension-preeclampsia is used to describe a wide spectrum of patients who may have only mild elevat...

journal_title：Current pharmaceutical design

authors： Coppage KH,Sibai BM

更新日期：2005-01-01 00:00:00

abstract：:Human arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) are polymorphic phase II xenobiotic-metabolising enzymes (XME) that acetylate arylamine compounds. They therefore play an important role in the detoxication and/or metabolic activation of certain therapeutic drugs, occupational chemicals and carcinogens. Alt...

journal_title：Current pharmaceutical design

authors： Rodrigues-Lima F,Dupret JM

更新日期：2004-01-01 00:00:00

abstract：:Various growth factors such as the platelet derived growth factor (PDGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) transduce their mitogenic signals through the activation of tyrosine kinase receptors (RTKs). Since en...

journal_title：Current pharmaceutical design

authors： Gouni-Berthold I,Sachinidis A

更新日期：2004-01-01 00:00:00

abstract：:Stem cell therapy heralds a new chapter in cardiovascular regenerative medicine. Cardiovascular implants are often used in both surgery and interventional cardiology. Cardiovascular stents are utilized in percutaneous coronary interventions (PCI), and are classified as either bare metal stents (BMS) or drug-eluting st...

journal_title：Current pharmaceutical design

authors： Tan A,Sumpio BE,Lee S,Seifalian AM

更新日期：2010-01-01 00:00:00

abstract：:Manufacturing of pharmaceutical solids involves different unit operations and processing steps such as powder blending, fluidization, sieving, powder coating, pneumatic conveying and spray drying. During these operations, particles come in contact with other particles, different metallic, glass or polymer surfaces and...

journal_title：Current pharmaceutical design

authors： Desai PM,Tan BM,Liew CV,Chan LW,Heng PW

更新日期：2015-01-01 00:00:00

abstract：:Large doses of omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are used to treat several diseases including hypertriglyceridemia in humans. Modest levels of EPA and DHA may be obtained from food, particularly from fatty fish. This review presents the literature examining the differences ...

journal_title：Current pharmaceutical design

authors： Abete P,Testa G,Galizia G,Della-Morte D,Cacciatore F,Rengo F

更新日期：2009-01-01 00:00:00

abstract：:Senescence is defined as an irreversible growth arrest that is characterised by a changed morphology, gene expression pattern and chromatin structure as well as an activated DNA damage response. Senescence has a dual role for tumour development-it acts as a tumour suppressor to prevent the proliferation of seriously d...

journal_title：Current pharmaceutical design

authors： Saretzki G

更新日期：2010-01-01 00:00:00

abstract：:Angiogenesis is the process by which new blood vessels are formed from preexisting microvasculature. To ensure an adequate blood supply, tumor cells release angiogenic factors that are capable of promoting nearby blood vessels to extend vascular branches to the tumor. In addition, larger tumors have been shown to rele...

journal_title：Current pharmaceutical design

authors： Gourley M,Williamson JS

更新日期：2000-03-01 00:00:00

abstract：OBJECTIVES:This paper reviews literary evidence on antithrombotic therapies currently employed in TAVR to assess validity and efficacy; duration and modality are also considered. In the absence of firm guidelines and reliable trial results, we analyze current knowledge of interaction between PPI and antithrombotic drug...

journal_title：Current pharmaceutical design

authors： Fusari M

更新日期：2013-01-01 00:00:00

abstract：:Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the ...

journal_title：Current pharmaceutical design

authors： Schaefer JR

更新日期：2011-01-01 00:00:00

abstract：:Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations of target-specific agents could counteract this response providing a useful strategy in ca...

journal_title：Current pharmaceutical design

authors： Porcelli L,Quatrale AE,Mantuano P,Silvestris N,Rolland JF,Biancolillo L,Paradiso A,Azzariti A

更新日期：2013-01-01 00:00:00

abstract：:Research on Substance P (SP) has, until recently, focused on its role in pain and inflammation. However, a report that NK(1) receptor antagonists have utility in the treatment of depression has stimulated research into the function of SP and the NK(1)receptor in anxiety and depression. The distribution of SP and the N...

journal_title：Current pharmaceutical design

authors： McLean S

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Cardiac resynchronization therapy (CRT) is a valuable intracardiac device--based treatment option for a subgroup of patients with advanced heart failure (HF) and QRS prolongation. However, still a significant proportion of patients do not benefit from CRT implantation, labeled as non-responders. OBJECTIVES:...

journal_title：Current pharmaceutical design

authors： Debska-Kozlowska A,Ksiazczyk M,Warchol I,Lubinski A

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:The 3' repair exonuclease 1 (TREX1) gene is the major DNA-specific 3'-5 'exonuclease of mammalian cells which reduces single- and double-stranded DNA (ssDNA and dsDNA) to prevent undue immune activation mediated by the nucleic acid. TREX1 is also a crucial suppressor of selfrecognition that pr...

journal_title：Current pharmaceutical design

authors： Tao SS,Wu GC,Zhang Q,Zhang TP,Leng RX,Pan HF,Ye DQ

更新日期：2019-01-01 00:00:00

abstract：:The ever-growing resistance of pathogens to antibiotics and crop disease due to pest has triggered severe health concerns in recent years. Consequently, there is a need of powerful and protective materials for the eradication of diseases. Metal/metal oxide nanoparticles (M/MO NPs) are powerful agents due to their ther...

journal_title：Current pharmaceutical design

authors： Chaudhary RG,Bhusari GS,Tiple AD,Rai AR,Somkuvar SR,Potbhare AK,Lambat TL,Ingle PP,Abdala AA

更新日期：2019-01-01 00:00:00

abstract：:These are exciting times for bioinformaticians, computational biologists and drug designers with the genome and proteome sequences and related structural databases growing at an accelerated pace. The post-genomic era has triggered high expectations for a rapid and successful treatment of diseases. However, in this bio...

journal_title：Current pharmaceutical design

authors： Soni A,Pandey KM,Ray P,Jayaram B

更新日期：2013-01-01 00:00:00

abstract：:Muscarinic acetylcholine receptors mediate diverse physiological functions. At present, five receptor subtypes (M(1) - M(5)) have been identified. The odd-numbered receptors (M(1), M(3), and M(5)) are preferentially coupled to G(q/11) and activate phospholipase C, which initiates the phosphatidylinositol trisphosphate...

journal_title：Current pharmaceutical design

authors： Ishii M,Kurachi Y

更新日期：2006-01-01 00:00:00

abstract：:Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and cl...

journal_title：Current pharmaceutical design

authors： Stoops WW,Rush CR

更新日期：2013-01-01 00:00:00

abstract：:G protein receptor kinase 2 (GRK2) has been for years mainly considered the negative regulator of the cardiac β adrenergic signaling. However GRK2 is a ubiquitous molecule and its kinase activity and scaffold properties brought to several investigations which have evidenced its involvement in pathophysiology of extra-...

journal_title：Current pharmaceutical design

authors： Ciccarelli M,Cipolletta E,Iaccarino G

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:New Oral Anticoagulants (NOACs) are effective and widely used to prevent and treat thromboembolic diseases, but the response to NOACs differs according to ABCB1 genotypes. OBJECTIVE:We investigated the effects of ABCB1 genotypes on the pharmacokinetics and clinical outcomes of NOACs. METHODS:We searched Pu...

journal_title：Current pharmaceutical design

authors： Xie Q,Xiang Q,Mu G,Ma L,Chen S,Zhou S,Hu K,Zhang Z,Cui Y,Jiang J

更新日期：2018-01-01 00:00:00

abstract：:We herein reviewed the mechanism underlying the gastric hyperemic response following barrier disruption, with a focus on cyclooxygenase (COX) isozymes, prostaglandin (PG) E2, and capsaicin-sensitive afferent neurons. Mucosal damage was induced by exposing the stomach to 20 mM taurocholate (TC) with 50 mM HCl. The TC t...

journal_title：Current pharmaceutical design

authors： Takeuchi K,Takeeda M,Amagase K,Nakashima M

更新日期：2015-01-01 00:00:00

abstract：:Mitochondria fulfill a number of essential cellular functions, being recognized that the strict regulation of the structure, function and turnover of these organelles is an immutable control node for the maintenance of neuronal integrity and homeostasis. Many lines of evidence posit that mitochondria constitute a conv...

journal_title：Current pharmaceutical design

authors： Correia SC,Cardoso S,Santos RX,Carvalho C,Santos MS,Perry G,Smith MA,Moreira PI

更新日期：2011-01-01 00:00:00

abstract：:Hereditary hemorrhagic telangiectasia (HHT) is characterized by vessel alterations such as dilatation of postcapillary venules and arterio-venous communications, which account for the major clinical manifestations of the disease. Two types of HHT have been characterized HHT-1 and HHT-2, respectively, depending the for...

journal_title：Current pharmaceutical design

authors： Jirillo E,Amati L,Suppressa P,Cirimele D,Guastamacchia E,Covelli V,Tafaro E,Sabbà C

更新日期：2006-01-01 00:00:00

abstract：:An important goal of biomedical research is to translate basic research findings into practical clinical implementation. Despite the advances in the technology used in drug discovery, the development of drugs for central nervous system diseases remains challenging. The failure rate for new drugs targeting important ce...

journal_title：Current pharmaceutical design

authors： Morofuji Y,Nakagawa S

更新日期：2020-01-01 00:00:00

abstract：:Cyclooxygenase-1 (COX-1) derived eicosanoids promote gastroprotective mucosal defenses and induce platelet aggregation. By sparing COX-1, COX-2 specific inhibitors provide effective anti-inflammatory and analgesic activity while substantially reducing the risk of peptic ulcer disease and GI bleeding compared to dual C...

journal_title：Current pharmaceutical design

authors： Scheiman JM

更新日期：2003-01-01 00:00:00

abstract：:The beneficial effect of antihypertensive treatment on the risk of major vascular events is well established. Several trials comparing older and newer drugs in the treatment of primary hypertension suggested that it is the blood pressure achieved, rather than choice of the drug that determines most of the primary outc...

journal_title：Current pharmaceutical design

authors： Karagiannis A,Mikhailidis DP,Kakafika AI,Tziomalos K,Athyros VG

更新日期：2007-01-01 00:00:00